Veradermics, Incorporated (NYSE: MANE) reported positive topline results on October 19, 2026, from Study 304, its randomised, double-blind, placebo-controlled Phase 3 clinical trial evaluating the investigational oral minoxidil formulation VDPHL01 in 536 men with mild-to-moderate pattern hair loss. The company reported that both once-daily and twice-daily dosing regimens met the trial’s co-primary endpoints at six months, demonstrating statistically significant improvements in non-vellus hair count and patient-reported hair coverage compared with placebo. The results add a second positive registration-directed dataset to Veradermics’ development programme, although VDPHL01 remains investigational and has not received United States Food and Drug Administration approval.
The findings are commercially and clinically significant because they provide additional controlled evidence for a formulation of minoxidil specifically developed for oral treatment of pattern hair loss. Minoxidil has an established history in hair growth treatment, but conventional oral formulations were originally developed for hypertension and are used off-label for hair loss. Veradermics aims to establish a dedicated oral product with a regulatory evidence package supporting its use in dermatology.
The latest trial strengthens the efficacy component of that strategy. However, the next stages of development will require a detailed assessment of longer-term tolerability, dose selection and the clinical implications of exposing patients with a non-life-threatening condition to a systemically administered vasodilator. The commercial opportunity may be substantial, but it will depend on how effectively the product differentiates itself from established and lower-cost alternatives.
What did the Phase 3 Study 304 results reveal about VDPHL01 hair growth efficacy?
Study 304 evaluated VDPHL01 at an 8.5 mg once-daily dose and an 8.5 mg twice-daily dose against placebo over six months. Participants in the once-daily group achieved a mean increase in non-vellus target area hair count of 28.6 hairs per square centimetre, while the twice-daily group recorded an increase of 36.4 hairs per square centimetre. The corresponding improvement in the placebo group was 6.6 hairs per square centimetre.
The placebo-adjusted mean differences were therefore approximately 22.0 hairs per square centimetre for once-daily administration and 29.8 hairs per square centimetre for twice-daily administration. Veradermics reported statistical significance at p<0.0001 for both active regimens compared with placebo. These measurements provide objective evidence of increased hair density within the assessed scalp area, although they should not be interpreted as the total number of additional hairs across an individual’s entire scalp.
The trial also evaluated patient-reported changes in hair coverage using the Androgenetic Alopecia Impact Rating Scale. At six months, 55.7% of participants receiving once-daily VDPHL01 and 68.7% receiving twice-daily treatment reported hair coverage that was improved or much improved. Only 15.0% of placebo participants reached the same response threshold.
Those results correspond to placebo-adjusted differences of 40.7 percentage points and 53.7 percentage points for the once-daily and twice-daily regimens, respectively. Both differences were reported as statistically significant, providing evidence that improvements in objectively measured hair count were accompanied by changes participants could perceive. That relationship is clinically relevant because hair count increases do not necessarily translate into an appearance improvement that patients consider meaningful.
Investigator assessments provided further supporting evidence. Veradermics reported that investigators considered hair coverage improved in 78.4% of once-daily recipients and 82.7% of twice-daily recipients at six months. Improvements were also observed at Month 2, the earliest evaluation time point, when the company reported statistically significant separation from placebo across hair count, patient-reported outcomes and investigator assessments.
The earlier assessment suggests that treatment effects can become measurable within the initial months of therapy. However, it does not establish when the first biological response occurred or whether every participant experienced a visible improvement within that period. Response variability and the persistence of benefits during continued treatment will remain important when the complete dataset becomes available.
How do the new Study 304 results compare with Veradermics’ earlier Study 302 findings?
The latest results reinforce positive topline findings reported in April 2026 from Study 302, a separate randomised, double-blind, placebo-controlled Phase 2/3 trial involving 519 men. In that study, the once-daily regimen produced a mean increase of 30.3 non-vellus hairs per square centimetre, while the twice-daily regimen produced a mean increase of 33.0 hairs per square centimetre. The placebo group recorded an increase of 7.3 hairs per square centimetre.
Both trials therefore reported favourable efficacy signals using similar dose regimens and assessment measures. Study 304 showed a somewhat larger numerical increase with twice-daily treatment than Study 302, while the once-daily results were numerically lower. These variations do not establish meaningful differences between the trials because individual study populations, baseline characteristics and random variation can influence observed outcomes.
Patient-reported results were also directionally consistent. Study 302 reported that 48.4% of once-daily recipients and 62.9% of twice-daily recipients achieved improved or much improved hair coverage, compared with 13.4% of placebo recipients. Study 304 reported corresponding active-treatment response rates of 55.7% and 68.7%, with a placebo response rate of 15.0%.
The replication of positive findings across two independently conducted registration-directed studies is more informative than a single successful readout. It reduces reliance on an isolated trial result and provides additional evidence that the treatment effect is reproducible under controlled conditions. However, the results remain company-reported topline findings, and detailed regulatory evaluation will require examination of the full efficacy and safety datasets.
Together, the two studies enrolled 1,055 male participants, making the combined programme a substantial controlled clinical investigation in pattern hair loss. The consistency of the objective and patient-reported outcomes strengthens the clinical development rationale, particularly because both endpoints address different aspects of treatment response. The remaining question is whether the complete evidence package demonstrates a sufficiently favourable benefit-risk profile for the intended long-term use.
What does the Phase 3 safety profile reveal about oral VDPHL01 treatment?
The most important qualification to the efficacy results concerns systemic safety. VDPHL01 contains minoxidil, a vasodilator originally developed as a treatment for severe hypertension. Conventional oral minoxidil has recognised cardiovascular risks, including fluid retention and other potentially serious complications, making the safety profile of a new extended-release formulation particularly relevant.
Veradermics reported that no treatment-related serious adverse events and no adverse events of special interest of cardiac origin were observed during the six-month placebo-controlled period of Study 304. The company also reported no clinically significant differences from placebo in heart rate, blood pressure or electrocardiogram measurements. These findings are encouraging within the observed trial population and follow-up period, but they do not establish the absence of cardiovascular risk during longer-term or broader clinical use.
The company’s investor presentation provides additional context concerning treatment-emergent adverse events. Approximately 42.1% of participants receiving once-daily VDPHL01 and 42.9% receiving twice-daily treatment experienced at least one treatment-emergent adverse event, compared with 28.2% of placebo participants. The higher overall event frequency in both active treatment groups is relevant when evaluating tolerability, even though most reported events were not classified as serious.
Treatment-emergent adverse events led to discontinuation in 2.2% of once-daily participants, 2.8% of twice-daily participants and 1.1% of placebo recipients. One serious treatment-emergent adverse event occurred in the twice-daily group, involving a humerus fracture that was not considered related to treatment. No treatment-related serious adverse events were reported in either active-dose group.
Peripheral oedema, a known concern associated with systemic minoxidil exposure, occurred in 2.8% of the once-daily group and 4.5% of the twice-daily group, compared with 0.6% of placebo participants. Hypertrichosis, or excessive hair growth outside the intended treatment area, was reported in 2.2% and 9.0% of participants receiving once-daily and twice-daily therapy, respectively. No placebo participants experienced hypertrichosis in Study 304.
These findings suggest that tolerability differs between the dosing regimens, although detailed analyses will be needed to understand the relationship between exposure, efficacy and adverse events. The higher hypertrichosis incidence with twice-daily administration is particularly relevant because the additional hair growth benefit must be evaluated against the increased likelihood of unwanted systemic effects. Determining the most appropriate dosing strategy will therefore involve more than selecting the regimen with the largest numerical hair count gain.
Can extended-release minoxidil offer a clinically meaningful alternative to existing hair loss treatments?
VDPHL01 uses a proprietary gel-matrix formulation designed to release minoxidil gradually over time. Veradermics believes that this extended-release approach can reduce the high peak blood concentrations associated with immediate-release oral formulations while maintaining sufficient exposure to support hair growth. The formulation strategy is intended to improve the balance between efficacy and systemic tolerability.
This pharmacological concept is relevant because oral minoxidil is already used off-label by some dermatologists for pattern hair loss. Such prescribing generally involves conventional formulations that were not specifically developed or approved for dermatological indications. A dedicated product supported by randomised registration-directed trials could provide clinicians with a more clearly defined evidence base for efficacy, dosing and adverse-event assessment.
However, a modified release profile does not automatically establish superiority over conventional oral minoxidil. Study 304 compared VDPHL01 with placebo rather than with immediate-release oral minoxidil or other active hair loss therapies. Consequently, the results cannot determine whether the proprietary formulation produces better hair growth, fewer adverse events or superior long-term adherence than existing treatment approaches.
For male pattern hair loss, established treatment options include topical minoxidil and oral finasteride, while conventional oral minoxidil is also used off-label. These treatments differ in their mechanisms, administration requirements and adverse-effect profiles. Veradermics would need to demonstrate a meaningful practical or clinical advantage to support differentiation in a market where several established options are already available.
The distinction between hormonal and non-hormonal approaches may also influence physician and patient preferences. Finasteride works through inhibition of the conversion of testosterone to dihydrotestosterone, whereas minoxidil promotes hair growth through a different pharmacological pathway. This difference may make a non-hormonal oral option attractive to some patients, although individual treatment suitability would remain a clinical consideration.
The twice-daily regimen introduces an additional commercial consideration because it requires more frequent administration than a once-daily alternative. Although Study 304 reported stronger numerical efficacy with twice-daily dosing, the higher incidence of some adverse events could influence patient preferences and eventual labelling considerations. The final regulatory assessment may therefore be important in determining how the available dose regimens are positioned.
How close is Veradermics to seeking FDA approval for VDPHL01 in male pattern hair loss?
The positive Study 304 results represent an important step towards a potential regulatory submission, but they are not equivalent to marketing approval. Veradermics now has positive six-month placebo-controlled topline findings from two registration-directed studies in men. The company must still complete the relevant evidence package, including longer-term safety information and the documentation required for a new drug application.
The registration-directed programme uses a 52-week study design consisting of a six-month placebo-controlled phase followed by a six-month extension period in which participants receive VDPHL01. That structure allows investigators to obtain controlled efficacy measurements during the initial period while gathering additional information about treatment exposure over a longer duration. The extension data are particularly relevant for a condition that commonly requires sustained treatment to maintain benefits.
Veradermics expects to report 12-month findings from Part B of Study 302 later in 2026. Those results could provide additional information about continued efficacy, treatment adherence, cardiovascular observations and discontinuations. They may also help clarify whether the safety findings observed during six months remain consistent over extended administration.
The FDA’s eventual review would be expected to examine the totality of efficacy and safety evidence, including the formulation’s pharmacokinetic characteristics and proposed labelling. Because minoxidil has recognised systemic effects, the adequacy of long-term monitoring and the proposed patient population could receive particular attention. Regulatory approval cannot be presumed solely because the two studies achieved statistical significance.
The programme also includes Study 306, a Phase 2/3 trial evaluating VDPHL01 in 556 women with mild-to-moderate pattern hair loss. That study uses lower 4.5 mg once-daily and twice-daily regimens, with topline data expected during the first half of 2027. The female development programme is distinct from the completed six-month male efficacy readouts and will require its own supporting evidence.
Veradermics previously reported positive findings from an open-label Phase 2 investigation in women, supporting its decision to pursue larger registration-directed development. However, the absence of a placebo control in that earlier study limits the conclusions that can be drawn from its efficacy findings. Results from Study 306 will therefore be important for determining whether the company’s broader male and female treatment strategy is supported by controlled evidence.
Could VDPHL01 become a commercially differentiated oral hair loss treatment?
Veradermics estimates that approximately 50 million men and 30 million women in the United States experience pattern hair loss. Those figures indicate a substantial underlying population, but they do not represent a directly accessible pharmaceutical market. Treatment uptake depends on factors including the severity of hair loss, willingness to pursue prescription therapy, affordability, clinician recommendations and patient expectations.
The commercial significance of VDPHL01 would depend partly on its ability to provide a differentiated alternative to inexpensive existing therapies. Conventional oral minoxidil is available as a generic medicine, while topical minoxidil products and oral finasteride have established positions in the treatment market. A branded extended-release formulation would need to justify its value through a combination of regulatory evidence, practical dosing, treatment experience and clinical outcomes.
Insurance reimbursement may represent an additional challenge because treatments for pattern hair loss are often subject to coverage limitations. Even with FDA approval, payer decisions and patient out-of-pocket costs could influence demand. The company may therefore need to develop a commercial strategy that accounts for substantial self-pay use alongside any available reimbursement pathways.
Veradermics entered the second half of 2026 with a strengthened financial position following its public offering and additional financing activities. At June 30, 2026, the company reported approximately $819.9 million in cash, cash equivalents and marketable securities. Management stated in August that its resources were expected to support operations into 2030, including multiple clinical milestones and preparations for a potential commercial launch.
That financial position gives Veradermics considerable flexibility to continue regulatory development and commercial preparations. Nevertheless, the transition from clinical-stage company to commercial pharmaceutical manufacturer requires investment in manufacturing, quality assurance, distribution, medical affairs and physician engagement. A strong balance sheet can support those activities, but it does not eliminate the need for a commercially viable product proposition.
VDPHL01’s potential value also extends beyond the initial male indication if the company’s female development programme produces positive results. However, each indication would require appropriate regulatory support, and approval for one population would not establish authorisation for the other. The anticipated Study 306 findings in 2027 are therefore an independent milestone rather than an extension of the completed male Phase 3 success.
What will determine whether positive VDPHL01 Phase 3 results translate into commercial success?
The Study 304 announcement materially strengthens the clinical evidence supporting VDPHL01. Veradermics has now reported two positive registration-directed male pattern hair loss studies demonstrating statistically significant gains in objectively measured hair count and patient-perceived hair coverage. The reproducibility of those findings provides a credible foundation for continuing regulatory development.
The next challenge is to establish the full benefit-risk profile of a systemically administered minoxidil formulation intended for potentially long-term treatment. The absence of treatment-related serious adverse events in Study 304 is encouraging, but the higher overall frequency of treatment-emergent adverse events and the observed incidence of peripheral oedema and hypertrichosis require appropriate consideration. Longer-term follow-up will be important in determining whether the favourable efficacy findings remain accompanied by acceptable tolerability.
Dose selection will also influence the product’s eventual clinical positioning. Twice-daily administration produced larger numerical hair count improvements and higher patient-reported response rates in Study 304, but also showed a greater incidence of certain adverse events. Clinicians and regulators will need to consider the practical implications of that trade-off rather than treating the highest observed efficacy measurement as the sole determinant of treatment value.
For investors and industry observers, the development moves Veradermics closer to a potential regulatory submission while leaving important questions about product differentiation and commercial execution unresolved. The next meaningful milestones are the 12-month Study 302 findings, completion of the regulatory evidence package and the company’s subsequent interaction with the FDA. Positive Study 306 results would provide an additional opportunity, but the initial male programme already faces a substantial test of its own.
The strength of Veradermics’ position is that it now has repeatable controlled efficacy findings rather than relying solely on an innovative formulation concept. Whether VDPHL01 becomes a widely used prescription treatment will depend on how the complete safety profile, eventual regulatory label and treatment economics compare with the options already available to dermatologists and patients.
